BICO AB (BICO) develops and markets bioprinting technologies that enable researchers to print three dimensional (3D) human organs and tissues. The company’s product portfolio encompasses bioprinters, and bioink.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

BICO conducts research to develop bioprint products, three-dimensional cell culture, cell line development, live cell imaging, as well as analysis. It is focused on product development related to 3D-printing, sample preparation kits for transcriptomic and single-cell sorting, live cell imaging, precision fluid delivery, and pre-clinical contract research services. The company's R&D division staffs over 255 scientists and engineers. It has more than 170 granted patents across 144 unique innovations spread over geographical coverage in mainly focused on the US and Europe and also includes Australia, South Korea, Japan, China and India. In FY2022, the company invested SEK363.3 million towards its research and development activities, amounting to 28.4% of the company's revenue.